Anti-hypertensive drugs have different effects on ventricular hypertrophy regression
Autor(a) principal: | |
---|---|
Data de Publicação: | 2010 |
Outros Autores: | , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/18342 |
Resumo: | OBJECTIVES: There is a direct relationship between the regression of left ventricular hypertrophy (LVH) and a decreased risk of mortality. This investigation aimed to describe the effects of anti-hypertensive drugs on cardiac hypertrophy through a meta-analysis of the literature. METHODS: The Medline (via PubMed), Lilacs and Scielo databases were searched using the subject keywords cardiac hypertrophy, antihypertensive and mortality. We aimed to analyze the effect of anti-hypertensive drugs on ventricle hypertrophy. RESULTS: The main drugs we described were enalapril, verapamil, nifedipine, indapamina, losartan, angiotensin-converting enzyme inhibitors and atenolol. These drugs are usually used in follow up programs, however, the studies we investigated used different protocols. Enalapril (angiotensin-converting enzyme inhibitor) and verapamil (Ca++ channel blocker) caused hypertrophy to regress in LVH rats. The effects of enalapril and nifedipine (Ca++ channel blocker) were similar. Indapamina (diuretic) had a stronger effect than enalapril, and losartan (angiotensin II receptor type 1 (AT1) receptor antagonist) produced better results than atenolol (selective β1 receptor antagonist) with respect to LVH regression. CONCLUSION: The anti-hypertensive drugs induced various degrees of hypertrophic regression. |
id |
USP-19_61dfad2b3d754cb1f51a36179f33ac4e |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/18342 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Anti-hypertensive drugs have different effects on ventricular hypertrophy regression HypertrophyCardiomyopathyHypertrophicLeft ventricle hypertensionCardiology OBJECTIVES: There is a direct relationship between the regression of left ventricular hypertrophy (LVH) and a decreased risk of mortality. This investigation aimed to describe the effects of anti-hypertensive drugs on cardiac hypertrophy through a meta-analysis of the literature. METHODS: The Medline (via PubMed), Lilacs and Scielo databases were searched using the subject keywords cardiac hypertrophy, antihypertensive and mortality. We aimed to analyze the effect of anti-hypertensive drugs on ventricle hypertrophy. RESULTS: The main drugs we described were enalapril, verapamil, nifedipine, indapamina, losartan, angiotensin-converting enzyme inhibitors and atenolol. These drugs are usually used in follow up programs, however, the studies we investigated used different protocols. Enalapril (angiotensin-converting enzyme inhibitor) and verapamil (Ca++ channel blocker) caused hypertrophy to regress in LVH rats. The effects of enalapril and nifedipine (Ca++ channel blocker) were similar. Indapamina (diuretic) had a stronger effect than enalapril, and losartan (angiotensin II receptor type 1 (AT1) receptor antagonist) produced better results than atenolol (selective β1 receptor antagonist) with respect to LVH regression. CONCLUSION: The anti-hypertensive drugs induced various degrees of hypertrophic regression. Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2010-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/1834210.1590/S1807-59322010000700012Clinics; Vol. 65 No. 7 (2010); 723-728 Clinics; v. 65 n. 7 (2010); 723-728 Clinics; Vol. 65 Núm. 7 (2010); 723-728 1980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/18342/20405Ferreira Filho, CelsoAbreu, Luiz Carlos deValenti, Vitor E.Ferreira, MarceloMeneghini, AdrianoSilveira, José AlexandreRiera, Andrés R. PérezColombari, EduardoMurad, NeifSantos-Silva, Paulo RobertoSilva, Lovian José Henrique Pereira daVanderlei, Luiz Carlos MarquesCarvalho, Tatiana D.Ferreira, Celsoinfo:eu-repo/semantics/openAccess2012-05-23T11:15:01Zoai:revistas.usp.br:article/18342Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2012-05-23T11:15:01Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Anti-hypertensive drugs have different effects on ventricular hypertrophy regression |
title |
Anti-hypertensive drugs have different effects on ventricular hypertrophy regression |
spellingShingle |
Anti-hypertensive drugs have different effects on ventricular hypertrophy regression Ferreira Filho, Celso Hypertrophy Cardiomyopathy Hypertrophic Left ventricle hypertension Cardiology |
title_short |
Anti-hypertensive drugs have different effects on ventricular hypertrophy regression |
title_full |
Anti-hypertensive drugs have different effects on ventricular hypertrophy regression |
title_fullStr |
Anti-hypertensive drugs have different effects on ventricular hypertrophy regression |
title_full_unstemmed |
Anti-hypertensive drugs have different effects on ventricular hypertrophy regression |
title_sort |
Anti-hypertensive drugs have different effects on ventricular hypertrophy regression |
author |
Ferreira Filho, Celso |
author_facet |
Ferreira Filho, Celso Abreu, Luiz Carlos de Valenti, Vitor E. Ferreira, Marcelo Meneghini, Adriano Silveira, José Alexandre Riera, Andrés R. Pérez Colombari, Eduardo Murad, Neif Santos-Silva, Paulo Roberto Silva, Lovian José Henrique Pereira da Vanderlei, Luiz Carlos Marques Carvalho, Tatiana D. Ferreira, Celso |
author_role |
author |
author2 |
Abreu, Luiz Carlos de Valenti, Vitor E. Ferreira, Marcelo Meneghini, Adriano Silveira, José Alexandre Riera, Andrés R. Pérez Colombari, Eduardo Murad, Neif Santos-Silva, Paulo Roberto Silva, Lovian José Henrique Pereira da Vanderlei, Luiz Carlos Marques Carvalho, Tatiana D. Ferreira, Celso |
author2_role |
author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Ferreira Filho, Celso Abreu, Luiz Carlos de Valenti, Vitor E. Ferreira, Marcelo Meneghini, Adriano Silveira, José Alexandre Riera, Andrés R. Pérez Colombari, Eduardo Murad, Neif Santos-Silva, Paulo Roberto Silva, Lovian José Henrique Pereira da Vanderlei, Luiz Carlos Marques Carvalho, Tatiana D. Ferreira, Celso |
dc.subject.por.fl_str_mv |
Hypertrophy Cardiomyopathy Hypertrophic Left ventricle hypertension Cardiology |
topic |
Hypertrophy Cardiomyopathy Hypertrophic Left ventricle hypertension Cardiology |
description |
OBJECTIVES: There is a direct relationship between the regression of left ventricular hypertrophy (LVH) and a decreased risk of mortality. This investigation aimed to describe the effects of anti-hypertensive drugs on cardiac hypertrophy through a meta-analysis of the literature. METHODS: The Medline (via PubMed), Lilacs and Scielo databases were searched using the subject keywords cardiac hypertrophy, antihypertensive and mortality. We aimed to analyze the effect of anti-hypertensive drugs on ventricle hypertrophy. RESULTS: The main drugs we described were enalapril, verapamil, nifedipine, indapamina, losartan, angiotensin-converting enzyme inhibitors and atenolol. These drugs are usually used in follow up programs, however, the studies we investigated used different protocols. Enalapril (angiotensin-converting enzyme inhibitor) and verapamil (Ca++ channel blocker) caused hypertrophy to regress in LVH rats. The effects of enalapril and nifedipine (Ca++ channel blocker) were similar. Indapamina (diuretic) had a stronger effect than enalapril, and losartan (angiotensin II receptor type 1 (AT1) receptor antagonist) produced better results than atenolol (selective β1 receptor antagonist) with respect to LVH regression. CONCLUSION: The anti-hypertensive drugs induced various degrees of hypertrophic regression. |
publishDate |
2010 |
dc.date.none.fl_str_mv |
2010-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/18342 10.1590/S1807-59322010000700012 |
url |
https://www.revistas.usp.br/clinics/article/view/18342 |
identifier_str_mv |
10.1590/S1807-59322010000700012 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/18342/20405 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 65 No. 7 (2010); 723-728 Clinics; v. 65 n. 7 (2010); 723-728 Clinics; Vol. 65 Núm. 7 (2010); 723-728 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222754835791872 |